NEW
YORK, June 28, 2023 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of Mersana
Therapeutics, Inc.:
On June 15, 2023, Mersana issued a
press release "announc[ing] that the U.S. Food and Drug
Administration (FDA) has issued a partial clinical hold pausing new
patient enrollment in UP-NEXT and UPGRADE-A, the company's ongoing
clinical trials of UpRi in platinum-sensitive ovarian cancer.
UPLIFT, Mersana's ongoing clinical trial of UpRi in
platinum-resistant ovarian cancer, completed enrollment in
October 2022." Mersana stated that
"[t]he partial clinical hold follows a submission by Mersana of a
recent aggregate safety report of all patients dosed with UpRi
(approximately 560 patients) evaluating bleeding events" and that
"Mersana's recent assessment determined that serious bleeding
events appear to occur at a higher rate than background. While most
bleeding cases in this aggregate safety analysis were low-grade,
five (<1%) Grade 5 (fatal) bleeding events were observed among
the approximately 560 patients dosed to date. The causes of
bleeding events remain under investigation." On this news,
Mersana's stock price fell $5.66 per
share, or 59.27%, to close at $3.89
per share on June 15, 2023.
Due to the forgoing, The Gross Law Firm is investigating
potential securities fraud claims on behalf of certain
Mersana investors. If you incurred a loss on your MRSN investment,
please contact us using the link below to discuss your rights.
https://securitiesclasslaw.com/securities/mersana-loss-submission-form/?id=41392&from=4
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/investigation-alert-the-gross-law-firm-notifies-shareholders-of-mersana-therapeutics-inc-of-an-investigation-and-potential-class-action-lawsuit--nasdaq-mrsn-301865109.html
SOURCE The Gross Law Firm